NASDAQ:AKRXAkorn Stock Price, Forecast & News

Akorn's stock was trading at $0.7630 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AKRX stock has decreased by 88.2% and is now trading at $0.09. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Akorn.

Akorn, Inc. (NASDAQ:AKRX) released its earnings results on Monday, May, 11th. The company reported $0.36 EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.45. The firm earned $204.69 million during the quarter, compared to analyst estimates of $168.90 million. Akorn had a positive return on equity of 8.53% and a negative net margin of 55.64%. View Akorn's earnings history.

2 equities research analysts have issued 12 month price targets for Akorn's stock. Their forecasts range from $2.00 to $4.00. On average, they anticipate Akorn's stock price to reach $3.00 in the next year. This suggests a possible upside of 3,233.3% from the stock's current price. View analysts' price targets for Akorn.

News coverage about AKRX stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Akorn earned a news sentiment score of 0.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutAkorn.

Akorn saw a increase in short interest in May. As of May 15th, there was short interest totaling 10,750,000 shares, an increase of 39.1% from the April 30th total of 7,730,000 shares. Based on an average daily trading volume, of 9,290,000 shares, the short-interest ratio is currently 1.2 days. Currently, 9.3% of the company's stock are sold short. View Akorn's Current Options Chain.

Some companies that are related to Akorn include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Zoetis (ZTS), Allergan (AGN), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

Akorn's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.32%), State Street Corp (2.36%), AQR Capital Management LLC (1.63%), Two Sigma Advisers LP (1.48%), Invesco Ltd. (1.09%) and Geode Capital Management LLC (1.08%). Company insiders that own Akorn stock include Alan D Weinstein, Christopher Young, Jonathan Kafer, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View institutional ownership trends for Akorn.

AKRX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Squarepoint Ops LLC, Two Sigma Investments LP, Geode Capital Management LLC, State Street Corp, BlackRock Inc., Spark Investment Management LLC, and GSA Capital Partners LLP. Company insiders that have sold Akorn company stock in the last year include Christopher Young, and Jonathan Kafer. View insider buying and selling activity for Akorn.

AKRX stock was acquired by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Invesco Ltd., Wells Fargo & Company MN, JPMorgan Chase & Co., and Nuveen Asset Management LLC. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer, and Terry Allison Rappuhn. View insider buying and selling activity for Akorn.

Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AKRX stock can currently be purchased for approximately $0.09.

Akorn has a market capitalization of $11.98 million and generates $682.43 million in revenue each year. The company earns $-226,770,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Akorn employs 2,227 workers across the globe.

The official website for Akorn is www.akorn.com.

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]